MILAN, Italy – Just a few decades ago, medical textbooks described spinal muscular atrophy (SMA), particularly its most severe forms, as a condition for which effective treatments capable of changing the course of the disease were largely unavailable. Today, that picture has changed dramatically. Thanks to advances in research, early...

CAMBRIDGE, Mass. — Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today presented new preclinical data at the 22nd Annual Meeting of the Oligonucleotide Therapeutics Society (OTS) demonstrating that SRP-1003, the company’s investigational small interfering RNA (siRNA) program for the treatment of myotonic dystrophy type...

MELBOURNE, Australia — Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments for chronic diseases including recurrent and metastatic cancer, today announced the publication of a peer-reviewed pilot study in Scientific Reports (Nature Publishing Group) titled “A formulation of pancreatic pro-enzymes provides...